Unity Biotechnology Inc (NASDAQ: UBX) has seen a rise in its stock price by 29.15 in relation to its previous close of 0.70. However, the company has experienced a 26.12% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-01 that SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the Company will present 36-week data from the ASPIRE Phase 2B study at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held on May 4-8, 2025 in Salt Lake City, Utah.
Is It Worth Investing in Unity Biotechnology Inc (NASDAQ: UBX) Right Now?
Company’s 36-month beta value is 1.06.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for UBX is 15.68M, and currently, short sellers hold a 4.78% ratio of that floaft. The average trading volume of UBX on June 10, 2025 was 172.93K shares.
UBX’s Market Performance
UBX’s stock has seen a 26.12% increase for the week, with a -1.34% drop in the past month and a -47.57% fall in the past quarter. The volatility ratio for the week is 3.20%, and the volatility levels for the past 30 days are at 4.68% for Unity Biotechnology Inc The simple moving average for the past 20 days is 20.84% for UBX’s stock, with a -33.57% simple moving average for the past 200 days.
Analysts’ Opinion of UBX
Many brokerage firms have already submitted their reports for UBX stocks, with H.C. Wainwright repeating the rating for UBX by listing it as a “Neutral.” The predicted price for UBX in the upcoming period, according to H.C. Wainwright is $2 based on the research report published on May 27, 2025 of the current year 2025.
Mizuho, on the other hand, stated in their research note that they expect to see UBX reach a price target of $1, previously predicting the price at $6. The rating they have provided for UBX stocks is “Neutral” according to the report published on May 16th, 2025.
Rodman & Renshaw gave a rating of “Buy” to UBX, setting the target price at $8 in the report published on August 22nd of the previous year.
UBX Trading at 1.85% from the 50-Day Moving Average
After a stumble in the market that brought UBX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.91% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at UBX starting from Nguyen Alexander Hieu, who sale 17,852 shares at the price of $1.03 back on Apr 02 ’25. After this action, Nguyen Alexander Hieu now owns 48,753 shares of Unity Biotechnology Inc, valued at $18,388 using the latest closing price.
Nguyen Alexander Hieu, the Officer of Unity Biotechnology Inc, proposed sale 17,852 shares at $1.03 during a trade that took place back on Apr 02 ’25, which means that Nguyen Alexander Hieu is holding shares at $18,305 based on the most recent closing price.
Stock Fundamentals for UBX
The total capital return value is set at -1.41. Equity return is now at value -231.27, with -61.66 for asset returns.
Based on Unity Biotechnology Inc (UBX), the company’s capital structure generated 1.01 points at debt to capital in total, while cash flow to debt ratio is standing at -1.18.
Currently, EBITDA for the company is -25.12 million with net debt to EBITDA at -0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.95.
Conclusion
In a nutshell, Unity Biotechnology Inc (UBX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
